Insulin Nph Hum/Reg Insulin Hm
Brand name: Humulin 70-30
Rank #185 of 500 drugs by total cost
$82.3M
Total Cost
177,501
Total Claims
$82.3M
Total Cost
7,961
Prescribers
$464
Cost per Claim
10,513
Beneficiaries
259,382
30-Day Fills
$10K
Avg Cost/Provider
22
Avg Claims/Provider
About Insulin Nph Hum/Reg Insulin Hm
Insulin Nph Hum/Reg Insulin Hm (sold as Humulin 70-30) was prescribed 177,501 times by 7,961 Medicare Part D providers in 2023, costing the program $82.3M. At $464 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 182 | Clopidogrel Bisulfate (Clopidogrel) | $84.7M | 5,428,304 |
| 183 | Famotidine (Famotidine) | $84.3M | 5,257,365 |
| 184 | Mifepristone (Korlym) | $83.3M | 2,397 |
| 185 | Insulin Nph Hum/Reg Insulin Hm (Humulin 70-30) | $82.3M | 177,501 |
| 186 | Montelukast Sodium (Montelukast Sodium) | $81.3M | 5,086,706 |
| 187 | Certolizumab Pegol (Cimzia) | $79.9M | 11,784 |
| 188 | Celecoxib (Celecoxib) | $77.7M | 1,938,505 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology